Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (early spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: domagrozumab, ramatercept, landogrozumab +3 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 1,455 | 0.73 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5251
Sealed predictions
- MSTN in dopamine neurons, braak+0.14 (p 0.723) → -0.36 (p 0.348)receipt 5259
Swarm cases
receipt 5259: MSTN in dopamine neurons, braak
- power
- full sample +0.03 (p 0.908, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.748, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.00 (p 0.997, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.16, sign flips 5; without severely affected donors +0.03 (p 0.908, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MSTN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts